NEW ANTIBACTERIAL DRUGS. Françoise Van Bambeke, PharmD, PhD
|
|
- Bonnie Brittany Hunt
- 5 years ago
- Views:
Transcription
1 EW ATIBACTERIAL DRUGS Drug pipeline for Gram-positive bacteria Françoise Van Bambeke, PharmD, PhD Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute Université catholique de Louvain, Brussels, Belgium < 25/04/2015 ECCMID - anti-gram positive pipeline
2 F. Van Bambeke s disclosures Research grants for work on investigational compounds discussed in this presentation from Cempra Pharmaceuticals Cerexa GSK Melinta therapeutics The Medicine Company MerLion Pharmaceuticals Theravance Trius ECCMID - anti-gram positive pipeline 2
3 ew antibiotics: what is your own view of the pipeline? 25/04/2015 ECCMID - anti-gram positive pipeline 3
4 ew antibiotics: where are we? Approvals by FDA/EMA systemic antibiotics 25/04/2015 ECCMID - anti-gram positive pipeline telavancin ceftaroline 4
5 ew antibiotics: where are we? Approvals by FDA/EMA systemic antibiotics 25/04/2015 ECCMID - anti-gram positive pipeline telavancin ceftaroline Shall we succeed? dalbavancin oritavancin tedizolid ceftazidime/avibactam ceftolozane/tazobactam 5
6 Anti Gram-positive recently approved drugs company drug class indications MRSA MDRSP VRE Theravance Telavancin Durata Ther. Dalbavancin The MedCo ritavancin lipoglycopeptide lipoglycopeptide lipoglycopeptide csssi / 25/04/2015 ECCMID - anti-gram positive pipeline HABP/VABP ABSSSI VanB only VanB only ABSSSI MSD Tedizolid oxazolidinone ABSSSI Forrest Astra-Zeneca Ceftaroline β-lactam ABSSSI / CABP Basilea Ceftobiprole* β-lactam CAP / HAP * licensed in 13 countries: AT, BE, CH, DE, DK, ES, FI, FR, IT, LU,, SE, UK; reimbursement and pricing authorization ongoing in most of them 6
7 dimerization prolonged half-life membrane anchoring decreased half-life Lipoglycopeptides 25/04/2015 ECCMID - anti-gram positive pipeline Van Bambeke, Cur. p. Pharmacol. 2004, 4: prolonged half-life 7
8 Cl Lipoglycopeptides: dual mode of action HC H oritavancin (lipoglycopeptide) H H H CH 3 H 2 H H H 3 C H 3 C CH 3 Cl H H H highly bactericidal activity on VR strains H H H H 25/04/2015 ECCMID - anti-gram positive pipeline Cl H CH 2 H H HCH 3 X transglycosylase Lipid II transpeptidase Van Bambeke et al, TIPS 2008, 29: D-Ala D-Ala L-Lys D-Glu L-Ala -acetylmuramic acid - -acetylglucosamine Pyrophosphate Lipid carrier 8
9 Lipoglycopeptides: pharmacokinetics parameter VA RI TLV TEC DAL Dosage 15 mg/kg 1200 mg 10 mg/kg 6 mg/kg 1000 mg Cmax (mg/l) AUC (mg.h/l) (%) prot. binding T ½ (h) (24h) 2800 (tot) 25/04/2015 ECCMID - anti-gram positive pipeline (24h) (tot) () 3-9 () 14 () 245 () single dose treatment 8 10 () 168 () 346 () once-a-week dose treatment (2 doses) 9
10 linezolid tedizolid tedizolid vs linezolid Locke et al, AAC (2010) 54: /04/2015 ECCMID - anti-gram positive pipeline Binding of tedizolid to methylated ribosomes 10
11 ceftaroline Resistance to -lactamases ceftobiprole ceftaroline and ceftobiprole Binding to PBP2a 25/04/2015 ECCMID - anti-gram positive pipeline allosteric site ceftaroline & PBP2a tero et al, PAS (2013) 110: catalytic site 11
12 Anti Gram-positive antibiotics in the pipeline (phases II/III) 1/2 company drug class status MRSA MDRSP VRE Cempra solithromycin ketolide Melinta delafloxacin fluoroquinolone TaiGen nemonoxacin fluoroquinolone Dong zabofloxacin fluoroquinolone Activis avarofloxacin fluoroquinolone MerLion finafloxacin fluoroquinolone GSK GSK topoisomerase inhibitor 25/04/2015 ECCMID - anti-gram positive pipeline CAPB ABSSSI CAPB / ABSSSI CAPB completed CAPB / ABSSSI ABSSSI Constructed based on respiratory / ABSSSI 12
13 Anti Gram-positive antibiotics in the pipeline (phases II/III) 1/2 company drug class status MRSA MDRSP VRE Cempra solithromycin ketolide Melinta delafloxacin fluoroquinolone TaiGen nemonoxacin fluoroquinolone Dong zabofloxacin fluoroquinolone Activis avarofloxacin fluoroquinolone MerLion finafloxacin fluoroquinolone GSK GSK topoisomerase inhibitor 25/04/2015 ECCMID - anti-gram positive pipeline CAPB ABSSSI CAPB / ABSSSI CAPB completed CAPB / ABSSSI ABSSSI Constructed based on respiratory / ABSSSI 13
14 increased activity solithromycin vs telithromycin lower interaction with nicotinic receptor Adapted from Van Bambeke, Ann. Med (2014) 46: /04/2015 ECCMID - anti-gram positive pipeline binding to ribosomal domain II poor recognition by pneumococci efflux pumps increased activity absence of inducibility of MLS B resistance solithromycin telithromycin 14
15 telithromycin : structure-toxicity relationship Inhibition of acetycholine nicotinic receptors vagus nerve (liver) liver failure ciliary ganglion (eye) visual disturbance neuro-muscular junction myastenia gravis exacerbation Adapted from Bertrand et al, AAC (2010) 54: /04/2015 ECCMID - anti-gram positive pipeline Role of telithromycin metabolites Metabolites T present for solithromycin 15
16 Solithromycin : pros and cons low MIC incl. ML R tissue distribution also active on intracell. organisms once daily administration IV/oral low interaction with nicotinic receptors potent anti-inflammatory effects substrate of CYP3A4 low cidal effect moderate activity against H. influenzae 25/04/2015 ECCMID - anti-gram positive pipeline 19
17 Anti Gram-positive antibiotics in the pipeline (phases II/III) 1/2 company drug class status MRSA MDRSP VRE Cempra solithromycin ketolide Melinta delafloxacin fluoroquinolone TaiGen nemonoxacin fluoroquinolone Dong zabofloxacin fluoroquinolone Activis avarofloxacin fluoroquinolone MerLion finafloxacin fluoroquinolone GSK GSK topoisomerase inhibitor 25/04/2015 ECCMID - anti-gram positive pipeline CAPB ABSSSI CAPB / ABSSSI CAPB completed CAPB / ABSSSI ABSSSI Constructed based on respiratory / ABSSSI 20
18 new (fluoro)quinolones JJ-Q2 Van Bambeke, Ann. Med (2014) 46: /04/2015 ECCMID - anti-gram positive pipeline BAY DW-224a WQ-3034; ABT-492; RX-3341 TG
19 Delafloxacin, the first non-zwitterionic quinolone H c a tio n ic F m icrospecies distributio n Cl H H 2 F F c a tio n ic H n e u tra l H D E L A F L X A C I n e u tra l F Cl H2 F p H F H H a n io n ic F Cl H 2 F a n io n ic F 25/04/2015 ECCMID - anti-gram positive pipeline 22 m icrospecies distributio n c a tio n ic c a tio n ic Van Bambeke, Future Microbiol. (in press); Lemaire et al, AAC (2011) 55: H 2 F CH 3 H H2 M X IF L X A C I zw itterionic F CH 3 a n io n ic zw itterionic a n io n ic p H H F CH 3
20 Delafloxacin, the first non-zwitterionic quinolone H c a tio n ic F m icrospecies distributio n Cl H H 2 c a tio n ic n e u tra l H n e u tra l Increased uptake by bacteria activity at acidic ph F F H D E L A F L X A C I F Cl H2 F p H F fluoroquinolone accumulation (ng. mg prot -1 / µg. ml -1 ) H H a n io n ic a n io n ic Van Bambeke, Future Microbiol. (in press); Lemaire et al, AAC (2011) 55: /04/2015 ECCMID - anti-gram positive pipeline F ** ** Cl H 2 ** F F * * moxifloxacin delafloxacin H 2 m icrospecies distributio n c a tio n ic F CH 3 c a tio n ic H H2 M X IF L X A C I zw itterionic F CH moxifloxacin delafloxacin p H a n io n ic H zw itterionic ph of broth fold difference in MIC relative to ph 7.4 (log 2 ) F CH 3 a n io n ic 23
21 new (fluoro)quinolones : pros and cons broad spectrum low MICs tissue distribution also active on intracell. organisms highly bactericidal once daily administration oral or IV delafloxacin / finafloxacin highly active at acidic ph broad spectrum cross resistance with other FQ AB class possibly showing rare/serious side effects CI in children/pregnancy 25/04/2015 ECCMID - anti-gram positive pipeline 30
22 Anti Gram-positive antibiotics in the pipeline (phases II/III) 1/2 company drug class status MRSA MDRSP VRE Cempra solithromycin ketolide 25/04/2015 ECCMID - anti-gram positive pipeline CAPB Melinta delafloxacin fluoroquinolone TaiGen nemonoxacin fluoroquinolone Dong zabofloxacin fluoroquinolone Activis avarofloxacin fluoroquinolone MerLion finafloxacin fluoroquinolone GSK GSK topoisomerase inhibitor CAPB / ABSSSI CAPB completed CAPB / ABSSSI ABSSSI Constructed based on respiratory / ABSSSI 31
23 FQ GSK topoisomerase inhibitor GSK o cross-resistance with fluoroquinolones Ehmann & Lahiri, Cur. p. Pharmacol. (2014) 18: /04/2015 ECCMID - anti-gram positive pipeline 32
24 GSK In vitro activity Isolates Associated with Lower Respiratory Tract and Skin Infections ICAAC (2013) F /04/2015 ECCMID - anti-gram positive pipeline 33
25 novel mode of action no cross-resistance with FQ broad spectrum bactericidal oral and IV routes no changes in ECG in Phase I GSK : pros and cons broad spectrum optimal dose still to be defined safety profile to be studied 25/04/2015 ECCMID - anti-gram positive pipeline 34
26 company drug class status MRSA MDRSP VRE Melinta radezolid oxazolidinone Paratek omadacycline aminomethyl cyclines Cempra fusidic acid fusidane Debiopharm Debio1452 FabI inhibitor Theravance CG TD-1792 FabI inhibitor glycopeptide + cephalosporine abriva lefamulin pleuromutilin Cellceutix Anti Gram-positive antibiotics in the pipeline (phases II/III) 2/2 brilacidin Crystalgenomics defensinmimetic 25/04/2015 ECCMID - anti-gram positive pipeline CAPB / ABSSSI CAPB / ABSSSI ABSSSI S. aureus ABSSSI ABSSSI / osteomyelitis completed Constructed based on csssi completed ABSSSI /CABP/HA-VABP completed ABSSSI 35
27 linezolid H biaryl spacer radezolid H F F radezolid vs linezolid H heteroaryl substituant H protonable aminated function sparsomycin linezolid Zhou et al., J. Bioorg. Med. Chem. Lett. (2008) 18: /04/2015 ECCMID - anti-gram positive pipeline 36
28 new oxazolidinones : pros and cons targeted spectrum still active on LZD R tissue distribution active on intracell. organisms once daily administration excellent oral bioavailability less platelet toxicity poorly or inactive on Gram(-) bacteriostatic safety profile to be further documented 25/04/2015 ECCMID - anti-gram positive pipeline 39
29 company drug class status MRSA MDRSP VRE Melinta radezolid oxazolidinone Paratek omadacycline aminomethyl cyclines Cempra fusidic acid fusidane Debiopharm Debio1452 FabI inhibitor Theravance CG TD-1792 FabI inhibitor glycopeptide + cephalosporine abriva lefamulin pleuromutilin Cellceutix Anti Gram-positive antibiotics in the pipeline (phases II/III) 2/2 brilacidin Crystalgenomics defensinmimetic 25/04/2015 ECCMID - anti-gram positive pipeline CAPB / ABSSSI CAPB / ABSSSI ABSSSI S. aureus ABSSSI ABSSSI / osteomyelitis completed Constructed based on csssi completed ABSSSI /CABP/HA-VABP completed ABSSSI 40
30 minocycline tigecycline omadacycline madacycline (PTK-0796) vs tigecycline Active if ribosomal protection Tet-mediated efflux Inactive if broad spectrum efflux (P. aeruginosa) Jenner et al., PAS (2013) 110: /04/2015 ECCMID - anti-gram positive pipeline 41
31 madacycline: pros and cons broad spectrum -> monotherapy still active on Tet R tissue distribution once daily administration oral and IV formulation broad spectrum inactive on P. aeruginosa bacteriostatic CI in children/pregnancy safety to be documented 25/04/2015 ECCMID - anti-gram positive pipeline 43
32 company drug class status MRSA MDRSP VRE Melinta radezolid oxazolidinone Paratek omadacycline aminomethyl cyclines Cempra fusidic acid fusidane Debiopharm Debio1452 FabI inhibitor Theravance CG TD-1792 FabI inhibitor glycopeptide + cephalosporine abriva lefamulin pleuromutilin Cellceutix Anti Gram-positive antibiotics in the pipeline (phases II/III) 2/2 brilacidin Crystalgenomics defensinmimetic 25/04/2015 ECCMID - anti-gram positive pipeline CAPB / ABSSSI CAPB / ABSSSI ABSSSI S. aureus ABSSSI ABSSSI / osteomyelitis completed Constructed based on csssi completed ABSSSI /CABP/HA-VABP completed ABSSSI 44
33 Fusidic acid Elongation factor G = GTP-ase ~ translocation of tra-mra Fusidic acid prevents EF-G release from the ribosome Gao et al., Science (2009) 326: /04/2015 ECCMID - anti-gram positive pipeline 45
34 active on CA-MRSA no cross resistance with other prot. synthesis inhibitors oral formulation [with loading dose] tissue distribution safety profile Fusidic acid: pros and cons resistance already spread in some countries frequent target mutations bacteriostatic substrate of CYP 3A4 25/04/2015 ECCMID - anti-gram positive pipeline 47
35 company drug class status MRSA MDRSP VRE Melinta radezolid oxazolidinone Paratek omadacycline aminomethyl cyclines Cempra fusidic acid fusidane Debiopharm Debio1452 FabI inhibitor Theravance CG TD-1792 FabI inhibitor glycopeptide + cephalosporine abriva lefamulin pleuromutilin Cellceutix Anti Gram-positive antibiotics in the pipeline (phases II/III) 2/2 brilacidin Crystalgenomics defensinmimetic 25/04/2015 ECCMID - anti-gram positive pipeline CAPB / ABSSSI CAPB / ABSSSI ABSSSI S. aureus ABSSSI ABSSSI / osteomyelitis completed Constructed based on csssi completed ABSSSI /CABP/HA-VABP completed ABSSSI 48
36 Debio1452 FabI (Enoyl-[acyl-carrier-protein] reductase) inhibitors Specifically active on S. aureus Fatty acid synthesis in bacteria Miesnel et al, ature Rev. Gen. (2003) 4: /04/2015 ECCMID - anti-gram positive pipeline 49 CG
37 Debio (AF) 1252 in vitro activity Karlowsky et al, AAC (2009) 53: /04/2015 ECCMID - anti-gram positive pipeline 50
38 novel mode of action restricted to S.aureus -> no effect on flora oral formulation tissue distribution FabI inhibitors: pros and cons bacteriostatic restricted to S.aureus 25/04/2015 ECCMID - anti-gram positive pipeline 51
39 company drug class status MRSA MDRSP VRE Melinta radezolid oxazolidinone Paratek omadacycline aminomethyl cyclines Cempra fusidic acid fusidane Debiopharm Debio1452 FabI inhibitor Theravance CG TD-1792 FabI inhibitor glycopeptide + cephalosporine abriva lefamulin pleuromutilin Cellceutix Anti Gram-positive antibiotics in the pipeline (phases II/III) 2/2 brilacidin Crystalgenomics defensinmimetic 25/04/2015 ECCMID - anti-gram positive pipeline CAPB / ABSSSI CAPB / ABSSSI ABSSSI S. aureus ABSSSI ABSSSI / osteomyelitis completed Constructed based on csssi completed ABSSSI /CABP/HA-VABP completed ABSSSI 52
40 Cephalosporin (THRX ) TD-1792 Long et al, J. Antibiot. (2008) 61: vancomycin 25/04/2015 ECCMID - anti-gram positive pipeline 53
41 TD-1792 : in vitro activity ICAAC (2007) F1-2110
42 bactericidal synergistic mode of action low MICs (incl. MRSA, VISA) Gram(+) spectrum once daily (IV) no metabolism (animals) TD-1792: pros and cons no anti Gram(-) coverage no oral route currently no sign of renal toxicity [VA] but more data needed 25/04/2015 ECCMID - anti-gram positive pipeline 57
43 company drug class status MRSA MDRSP VRE Melinta radezolid oxazolidinone Paratek omadacycline aminomethyl cyclines Cempra fusidic acid fusidane Debiopharm Debio1452 FabI inhibitor Theravance CG TD-1792 FabI inhibitor glycopeptide + cephalosporine abriva lefamulin pleuromutilin Cellceutix Anti Gram-positive antibiotics in the pipeline (phases II/III) 2/2 brilacidin Crystalgenomics defensinmimetic 25/04/2015 ECCMID - anti-gram positive pipeline CAPB / ABSSSI CAPB / ABSSSI ABSSSI S. aureus ABSSSI ABSSSI / osteomyelitis completed Constructed based on csssi completed ABSSSI /CABP/HA-VABP completed ABSSSI 58
44 lefamulin Lefamulin (BC-3781) vs retapamulin Antibiotic binding to peptidyl transferase center of 50S ribosome Schlünzen et al, Mol. Microbiol. (2004) 54: retapamulin 25/04/2015 ECCMID - anti-gram positive pipeline 59
45 novel mode of action infrequent cross resistance with other classes broad spectrum ELF penetration accumulation in cells first for systemic use in humans topic, oral, IV no major CYP interactions Lafamulin: pros and cons cross resistance described with LZD (cfr, PTC mutations) broad veterinary use of other pleuromutilins not active on enterobacteriacae 25/04/2015 ECCMID - anti-gram positive pipeline 61
46 company drug class status MRSA MDRSP VRE Melinta radezolid oxazolidinone Paratek omadacycline aminomethyl cyclines Cempra fusidic acid fusidane Debiopharm Debio1452 FabI inhibitor Theravance CG TD-1792 FabI inhibitor glycopeptide + cephalosporine abriva lefamulin pleuromutilin Cellceutix Anti Gram-positive antibiotics in the pipeline (phases II/III) 2/2 brilacidin Crystalgenomics defensinmimetic 25/04/2015 ECCMID - anti-gram positive pipeline CAPB / ABSSSI CAPB / ABSSSI ABSSSI S. aureus ABSSSI ABSSSI / osteomyelitis completed Constructed based on csssi completed ABSSSI /CABP/HA-VABP completed ABSSSI 62
47 25/04/2015 Brilacidin membrane depolarisation ~ daptomycin cytoplasmic protein misfolding upregulation of chaperones and proteases (genes involved in stress response) ~ defensins Mensa et al, AAC (2014) 58: ECCMID - anti-gram positive pipeline 63
48 Brilacidin: phase II data 25/04/2015 ECCMID - anti-gram positive pipeline 64
49 novel mode of action rapidly bactericidal mimic human defenses broad spectrum active on stationary phase bact. short treatment (1-3 doses) Brilacidin: pros and cons IV administration small V d gender differences in PK (Cl and body surface) reversible adverse effects (paresthesia, blood pressure and heart rate) 25/04/2015 ECCMID - anti-gram positive pipeline 65
50 Antibiotic pipeline: did you change your mind? Large number of molecules in clinical development much more in preclinical development More advanced molecules () are new derivatives in existing classes with improved properties (MIC resistance PK- safety) 25/04/2015 ECCMID - anti-gram positive pipeline 66
51 Antibiotic pipeline: some work ahead Susceptibility Breakpoint harmonization An example with MRSA antibiotic EUCAST CLSI/FDA S R > S R rifampicin azithromycin doxycycline vancomycin linezolid ceftaroline telavancin dalbavancin rule in Europe! 25/04/2015 ECCMID - anti-gram positive pipeline 67
52 Antibiotic pipeline: can we do better? Equivalence to current options in comparative clinical trials This will raise issues for reimbursement, especially against the generics of the comparators used in these studies eed to design superiority trials and to focus pricing and reimbursement for documented cases of infection by resistant organisms 25/04/2015 ECCMID - anti-gram positive pipeline 68
53 on-inferiority vs superiority trials? -IFERIRITY if evidence of spontaneous resolution rate (more effective than placebo) Indications (and delta): Community-acquired pneumonia (-10%; more in PRT scores of IV-V) Hospital-acquired pneumonia and ventilator-associated pneumonia (less than -12.5%) Skin and soft tissue infections (-10%) Intra-abdominal infections (-12.5%) Urinary tract infections (-10 %) SUPERIRITY if spontaneous resolution (placebo effective) Acute bacterial maxillary sinusitis Acute bacterial exacerbations of chronic bronchitis Acute otitis media Superficial skin infections (such as impetigo and minor wounds) Inhaled antibacterial agents (excl. CF) LIMITED TRIALS Rare MDR organisms Few patients EMA/CHMP/351889/2013 DRUG/comparator trial Placebo/ DRUG/comparator trial DRUG non comparative trial 25/04/2015 ECCMID - anti-gram positive pipeline 69
54 on-inferiority vs superiority trials? 25/04/2015 ECCMID - anti-gram positive pipeline 70
55 What about the future? 25/04/2015 ECCMID - anti-gram positive pipeline 71
56 Backup slides 25/04/2015 ECCMID - anti-gram positive pipeline 72
57 Study number & development Phase CT ; Phase I CT ; CT ; CT ; CT ; solithromycin: ongoing clinical trials Drugs and doses Study title Status Solithromycin; dose not specified ral solithromycin (800 mg QD day 1; 400 mg QD days 2-5) ; comparator: oral levofloxacin (750 mg QD days 1-5) Single dose solithromycin 1000 mg by oral route Solithromycin (intravenous with the potential step-down to oral); comparator: moxifloxacin (intravenous with the potential step-down to oral); doses not specified Solithromycin (800 mg orally on day 1 followed by 400 mg daily on days 2 through 5, followed by placebo on days 6 and 7); comparator: moxifloxacin (400 mg orally on Day 1 to 7) Van Bambeke, Ann. Med (2014) 46: /04/2015 ECCMID - anti-gram positive pipeline Pharmacokinetics and Safety of Solithromycin Capsules in Adolescents Efficacy and Safety Study of ral CEM- 101 Compared to ral Levofloxacin in Treatment of Patients With Community- Acquired Bacterial Pneumonia Safety and Efficacy Study of Single-Dose ral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea Efficacy and Safety Study of Intravenous to ral Solithromycin (CEM-101) Compared to Intravenous to ral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia (SLITAIRE-IV) Efficacy and Safety Study of ral Solithromycin (CEM-101) Compared to ral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia (SLITAIRE-RAL) Recruiting Completed (2011) Completed (2013) Recruiting Recruiting 73
58 Study number & development Phase CT ; Phase I CT ; CT ; CT ; CT ; solithromycin: ongoing clinical trials Drugs and doses Study title Status Solithromycin; dose not specified ral solithromycin (800 mg QD day 1; 400 mg QD days 2-5) ; comparator: oral levofloxacin (750 mg QD days 1-5) Single dose solithromycin 1000 mg by oral route Solithromycin (intravenous with the potential step-down to oral); comparator: moxifloxacin (intravenous with the potential step-down to oral); doses not specified Solithromycin (800 mg orally on day 1 followed by 400 mg daily on days 2 through 5, followed by placebo on days 6 and 7); comparator: moxifloxacin (400 mg orally on Day 1 to 7) Van Bambeke, Ann. Med (2014) 46: /04/2015 ECCMID - anti-gram positive pipeline Pharmacokinetics and Safety of Solithromycin Capsules in Adolescents Efficacy and Safety Study of ral CEM- 101 Compared to ral Levofloxacin in Treatment of Patients With Community- Acquired Bacterial Pneumonia Safety and Efficacy Study of Single-Dose ral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea Efficacy and Safety Study of Intravenous to ral Solithromycin (CEM-101) Compared to Intravenous to ral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia (SLITAIRE-IV) Efficacy and Safety Study of ral Solithromycin (CEM-101) Compared to ral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia (SLITAIRE-RAL) Recruiting Completed (2011) Completed (2013) Recruiting Recruiting 74
59 solithromycin : CABP data ldach et al, AAC (2013) 57: /04/2015 ECCMID - anti-gram positive pipeline 75
60 new (fluoro)quinolones: in vitro activity as or more active ~ moxifloxacin, but cross resistance Adapted from Van Bambeke, Ann. Med (2014) 46: /04/2015 ECCMID - anti-gram positive pipeline 76
61 Study number & development Phase ZABFLXACI CT ; CT ; new (fluoro)quinolones: ongoing clinical trials Drugs and doses Study title Status Zabofloxacin (400 mg orally QD for 3 or 5 days); comparator: levofloxacin (500 mg orally QD for 7 days) Zabofloxacin (400 mg orally QD); comparator: moxifloxacin (400 mg orally QD) Adapted from Van Bambeke, Ann. Med (2014) 46: /04/2015 ECCMID - anti-gram positive pipeline Safety and Efficacy Study of ral Zabofloxacin in Community Acquired Pneumonia A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg (DW224-III-3) after Multi-dose ral Administration in Patients With Acute Bacterial Exacerbation of Chronic bstructive Pulmonary Disease. Completed (2012) ngoing, not recruiting 77
62 Study number & development Phase EMXACI CT ; CT ; CT ; CT ; CT ; new (fluoro)quinolones: ongoing clinical trials ot provided Drugs and doses Study title Status emonoxacin 750 mg, oral administration, once daily for 7±1 and 14±1 days emonoxacin (750 mg orally 2 tablets or 500 mg orally 3 tablets) ; comparator: levofloxacin (500 mg orally QD + placebo) for 7 days emonoxacin (500 mg or 650 mg QD IV for 7~14 days) ; comparator: moxifloxacin (400 mg QD IV for 7~14 days) emonoxacin (500 mg orally) ; comparator levofloxacin (500 mg orally) for 7~14 days Adapted from Van Bambeke, Ann. Med (2014) 46: /04/2015 ECCMID - anti-gram positive pipeline Safety and Efficacy Comparison of TG (emonoxacin) to Levofloxacin in Community-Acquired Pneumonia Safety and Efficacy Study of TG (emonoxacin) in Diabetic Foot Infections Study to Assess the Efficacy and Safety of emonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP) Study to Evaluate the Efficacy and Safety of Intravenous Infusion With TG (nemonoxacin) Versus Moxifloxacin in Treating Adult Patients With Community Acquired Pneumonia (CAP) Study to Evaluate the Efficacy and Safety of ral Administration With emonoxacin and Levofloxacin in Patients With Community-acquired Pneumonia (CAP) ot provided Completed (2009) Completed (2010) Recruiting Completed (2012) 78
63 Study number & development Phase EMXACI CT ; CT ; CT ; CT ; CT ; new (fluoro)quinolones: ongoing clinical trials ot provided Drugs and doses Study title Status emonoxacin 750 mg, oral administration, once daily for 7±1 and 14±1 days emonoxacin (750 mg orally 2 tablets or 500 mg orally 3 tablets) ; comparator: levofloxacin (500 mg orally QD + placebo) for 7 days emonoxacin (500 mg or 650 mg QD IV for 7~14 days) ; comparator: moxifloxacin (400 mg QD IV for 7~14 days) emonoxacin (500 mg orally) ; comparator levofloxacin (500 mg orally) for 7~14 days Adapted from Van Bambeke, Ann. Med (2014) 46: /04/2015 ECCMID - anti-gram positive pipeline Safety and Efficacy Comparison of TG (emonoxacin) to Levofloxacin in Community-Acquired Pneumonia Safety and Efficacy Study of TG (emonoxacin) in Diabetic Foot Infections Study to Assess the Efficacy and Safety of emonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP) Study to Evaluate the Efficacy and Safety of Intravenous Infusion With TG (nemonoxacin) Versus Moxifloxacin in Treating Adult Patients With Community Acquired Pneumonia (CAP) Study to Evaluate the Efficacy and Safety of ral Administration With emonoxacin and Levofloxacin in Patients With Community-acquired Pneumonia (CAP) ot provided Completed (2009) Completed (2010) Recruiting Completed (2012) 79
64 emonoxacin CABP phase III data Van Rensburg et al, AAC (2010) 54: /04/2015 ECCMID - anti-gram positive pipeline 80
65 Study number & development Phase DELAFLXACI CT ; CT ; CT ; CT ; new (fluoro)quinolones: ongoing clinical trials Drugs and doses Study title Status Delafloxacin (300 mg or 450 mg IV BID) Safety and Efficacy Study of a Completed (2008) ; comparator: tigecycline (100 mg on Fluoroquinolone to Treat Complicated Skin Infections day 1 then 50 mg IV BID) Delafloxacin (300mg IV BID) for 5-14 A Study to Assess bjective Endpoint Completed (2011) days; Measurements of Response in Bacterial comparators: linezolid (600mg IV BID) Skin Infections and vancomycin (15mg/kg, up to 1250 mg, IV BID) for 5-14 days Delafloxacin (300 mg IV BID) for up 5- Delafloxacin Versus Vancomycin and Recruiting 14 days; Aztreonam for the Treatment of Acute comparator: vancomycin (15mg/kg IV) Bacterial Skin and Skin Structure Infections + aztreonam (2g) BID Delafloxacin (300 mg IV BID 300mg iv Delafloxacin vs Vancomycin and ot yet recruiting BID for 3 days) followed by 450mg oral Aztreonam for the Treatment of Acute BID for up 5-14 days total; Bacterial Skin and Skin Structure Infections comparator: vancomycin (15mg/kg IV) + aztreonam (2g) BID Adapted from Van Bambeke, Ann. Med (2014) 46: /04/2015 ECCMID - anti-gram positive pipeline 81
66 Radezolid vs linezolid Locke et al, AAC (2010) 54: /04/2015 ECCMID - anti-gram positive pipeline 82
67 cellular accumulation Radezolid cellular pharmacokinetics in macrophages Cellular accumulation Radezolid Linezolid time (min) Q/ Subcellular distribution AB Cytx RDZ density accumulation in acidic vacuoles Lemaire et al., AAC (2010) 54: lacticodehydrogenase (LDH) cytochrome C oxydase lysosome mitochondria 25/04/2015 ECCMID - anti-gram positive pipeline 83 (Cytx) -acetyl--glucosaminidase (AB)
68 madacycline : CSSSI data madacycline 100 mg [i.v.] QD; possible transition to 200 mg [p.o.] QD linezolid 600 mg [i.v.] BID; possible transition to 600 mg [p.o.]y BID oel et al., AAC (2012) 56: /04/2015 ECCMID - anti-gram positive pipeline 84
69 TD-1792 : in vivo activity ICAAC (2007)
70 TD-1792 : csssi data TD-1792 : 2 mg/kg once daily vs vancomycin 1 g twice daily Stryjewski et al, AAC (2012) 56:
71 Lefamulin: ABSSSI data ICAAC (2012) L /04/2015 ECCMID - anti-gram positive pipeline 87
The new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining?
S. aureus: what do we need to know (and to do) in 2007? The new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining? Françoise Van Bambeke Unité de Pharmacologie
More informationTherapeutic options: what s new in the pipeline?
Therapeutic options: what s new in the pipeline? Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology & Centre for Clinical Pharmacy Louvain Drug Research Institute, Université catholique de Louvain,
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationAntimicrobials Update
Antimicrobials Update Rosie Amini, PharmD. BCPS Antimicrobial Stewardship Program Coordinator Swedish Medical Center Disclosures: Dr. Amini has no significant financial interest in any of the products
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationNovel therapies & the role of early switch and early discharge protocols for management of MRSA infections
Novel therapies & the role of early switch and early discharge protocols for management of MRSA infections Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology & Centre for Clinical Pharmacy Louvain
More informationContribution of new antibiotics to current and future challenges of main Gram-positive infections
Contribution of new antibiotics to current and future challenges of main Gram-positive infections Paul M. Tulkens, MD, PhD Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute, Université
More informationLefamulin: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM
: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM Department of Critical Care, University Hospital ATTIKON National and Kapodistrian University of Athens, Medical School
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
More informationThe role of new antibiotics in the treatment of severe infections: Safety and efficacy features
The role of new antibiotics in the treatment of severe infections Safety and efficacy features Christian Eckmann Hannover, Germany The role of new antibiotics in the treatment of severe infections: Safety
More informationAntimicrobial development: Overview and Update. Sumati Nambiar MD MPH Division of Anti-Infective Products FDA
Antimicrobial development: Overview and Update Sumati Nambiar MD MPH Division of Anti-Infective Products FDA American College of Physicians, Washing ton Chapter November 17, 2012 Disclaimer The views expressed
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationICAAC. Key words: antibacterial agent development approval. linezolid β. chloramphenicol tetracycline colistin mupirocin teicoplanin
16 11 1 16 11 25 58 238 154 β 65 25 24 20 10 46 10 19 5 10 10 10 ICAAC Key words: antibacterial agent development approval 1946 60 238 10 Fig. 1 β 95 40 1976 1995 20 60 β β 40 chloramphenicol tetracycline
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationNew Antibiotics for MRSA
New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationAntibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi
Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What
More informationCeftaroline: a new antibiotic for your patients?
Ceftaroline: a new antibiotic for your patients? Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Louvain Drug Research Institute Université catholique de Louvain Brussels, Belgium 11 February
More informationMRSA treatment: does the future shine? Françoise Van Bambeke & Paul M. Tulkens Unité de Pharmacologie cellulaire et moléculaire.
MRSA treatment: does the future shine? Françoise Van Bambeke & Paul M. Tulkens Unité de Pharmacologie cellulaire et moléculaire UCL - Brussels MRSA : where are there? At home! And here too! Deplano et
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationAntibiotics and Stewardship: What s New in Pediatrics-Land?
Antibiotics and Stewardship: What s New in Pediatrics-Land? Sean P. Elliott, MD Professor of Pediatrics Associate Chair of Education, Department of Pediatrics University of Arizona College of Medicine
More informationFuture design of (comparative) clinical trials or how to bring antibiotics to the bed side
Future design of (comparative) clinical trials or how to bring antibiotics to the bed side Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Louvain Drug Research Institute Université catholique
More informationFor analyst certification and disclosures please see page 7
Physician Survey Survey of Healthcare Professionals on Community-Acquired Bacterial Pneumonia We conducted a survey on prescribing habits for community-acquired bacterial pneumonia (CABP) in order to better
More informationSkin and Soft Tissue Infections Emerging Therapies and 5 things to know
2011 MFMER slide-1 Skin and Soft Tissue Infections Emerging Therapies and 5 things to know Aaron Tande, MD Assistant Professor of Medicine October 27, 2017 Division of INFECTIOUS DISEASES 2011 MFMER slide-2
More informationChoose Your Own Antibiotic/Adventure Gram-Positive Style
Disclosures Consultant for Cubist Pharmaceuticals, Inc Research support from Forest Laboratories Choose Your Own Antibiotic/Adventure Gram-Positive Style I have never seen Star Wars (But I m a big fan
More informationnumber Done by Corrected by Doctor Dr Hamed Al-Zoubi
number 8 Done by Corrected by Doctor Dr Hamed Al-Zoubi 25 10/10/2017 Antibacterial therapy 2 د. حامد الزعبي Dr Hamed Al-Zoubi Antibacterial therapy Figure 2/ Antibiotics target Inhibition of microbial
More informationAntimicrobial agents. are chemicals active against microorganisms
Antimicrobial agents are chemicals active against microorganisms Antibacterial Agents Are chemicals active against bacteria Antimicrobials Antibacterial Antifungal Antiviral Antiparasitic: -anti protozoan
More informationTDM of antibiotics. Paul M. Tulkens, MD, PhD
TDM of antibiotics (Laboratory testing guideline in the intensive care unit) Paul M. Tulkens, MD, PhD Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute, Université catholique de Louvain,
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationIntracellular Activity of Antibiotics: the knowns, the uncertainties and the failures
Intracellular Activity of Antibiotics: the knowns, the uncertainties and the failures Paul M. Tulkens, MD, PhD * Emeritus Professor of Pharmacology Invited Lecturer (Drug Discovery & Development / Rational)
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationActivity of antibiotics against extracellular and intracellular forms of Staphylococcus aureus
Maritza Barcia-Macay (Patterson) Unité de Pharmacologie cellulaire et moléculaire Activity of antibiotics against extracellular and intracellular forms of Staphylococcus aureus Pharmacodynamic studies
More informationAntimicrobial Therapy
Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the
More informationImproving antibiotic targeting in vivo
EXT GEERATI SUSCEPTIBILITY TESTIG: WHAT WRKS? Improving antibiotic targeting in vivo Françoise Van Bambeke, PharmD, PhD Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute Université
More informationPK/PD to fight resistance
PK/PD to fight resistance Eradicate Abnormal bacteria Mutations Efflux pumps Mutation-Preventing Concentration Breakpoint values for T > MIC and in practice With the support of Wallonie-Bruxelles-International
More informationStaph Cases. Case #1
Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationPrinciples of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1
Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination
More informationMRSA ventilatorassociated
MRSA ventilatorassociated pneumonia Jean Chastre, M.D. www.reamedpitie.com Conflicts of interest Consulting or lecture fees: Medimmune/Astrazeneca, Bayer, Pfizer, Arsanis, Cubist/Merck, Basilea, Aridis,
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationCO-ACTION. Prof.dr. J.W. Mouton. Note : some technical and all results slides were removed. JPIAMR JWM Paris JWM Paris 2017
CO-ACTION Prof.dr. J.W. Mouton Note : some technical and all results slides were removed JPIAMR 1 Clinical Development of (old drug) combinations : essentials Potency of combination CoAction PK profiling
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationGORILLACILLINS IN THE ICU:
Conflicts of Interest None to declare GORILLACILLINS IN THE ICU: From SPACE and Beyond... Tim T.Y. Lau, PharmD, FCSHP Clinical Pharmacy Specialist in Infectious Diseases Pharmaceutical Sciences, Vancouver
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationAntimicrobials & Resistance
Antimicrobials & Resistance History 1908, Paul Ehrlich - Arsenic compound Arsphenamine 1929, Alexander Fleming - Discovery of Penicillin 1935, Gerhard Domag - Discovery of the red dye Prontosil (sulfonamide)
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationon February 12, 2018 by guest
AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of
More informationEinheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationfolate-derived cofactors purines pyrimidines Sulfonamides sulfa drugs Trimethoprim infecting bacterium to perform DNA synthesis cotrimoxazole
Folate Antagonists Enzymes requiring folate-derived cofactors are essential for the synthesis of purines and pyrimidines (precursors of RNA and DNA) and other compounds necessary for cellular growth and
More informationIs erythromycin bactericidal
Is erythromycin bactericidal Search Comparison of erythromycin, clarithromycin, azithromycin, telithromycin, roxithromycin: mechanism of action, spectrum of activity, side effects, drug interactions. Erythromycin
More informationIntroduction to Antimicrobials. Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail.
Introduction to Antimicrobials Rachel J. Gordon, MD, MPH Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail. Major Learning Objectives: 1) Learn the different
More informationEUCAST Expert Rules for Staphylococcus spp IF resistant to isoxazolylpenicillins
EUAST Expert Rules for 2018 Organisms Agents tested Agents affected Rule aureus Oxacillin efoxitin (disk diffusion), detection of meca or mec gene or of PBP2a All β-lactams except those specifically licensed
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationIntroduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018
Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationSIVEXTRO (tedizolid phosphate) oral tablet ZYVOX (linezolid) oral suspension and tablet
ZYVOX (linezolid) oral suspension and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More informationAntibiotics & Resistance
What are antibiotics? Antibiotics & esistance Antibiotics are molecules that stop bacteria from growing or kill them Antibiotics, agents against life - either natural or synthetic chemicals - designed
More informationNew Antibiotics & New Insights into Old Antibiotics
New Antibiotics & New Insights into Old Antibiotics Louisiana Chapter of the American Academy of Pediatrics August 18, 2018 Baton Rouge, Louisiana John Bradley MD Rady Children s Hospital San Diego University
More informationDETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams
DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for
More informationCME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationAnimal models and PK/PD. Examples with selected antibiotics
Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationKeywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing
Journal of Antimicrobial Chemotherapy (2004) 53, Suppl. S1, i3 i20 DOI: 10.1093/jac/dkh050 Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review
More informationDiscussion Points. Decisions in Selecting Antibiotics
Antibiotics in Acute Care Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical
More informationChoosing an Antibiotic
Principles of Antibiotic Use - The 6 Step Plan Robin J Green MBBCh, DCH, FC Paed, DTM&H, MMed, FCCP, PhD, Dip Allergy, FAAAAI Department of Paediatrics and Child Health 1 Choosing an Antibiotic Disease/Site
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationWHY IS THIS IMPORTANT?
CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationDeveloping Well-Differentiated Antibiotics. June 2017 Mark Hahn Chief Financial Officer
Developing Well-Differentiated Antibiotics June 2017 Mark Hahn Chief Financial Officer Forward Looking Statements This presentation contains forward-looking statements regarding future events. These statements
More informationLefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results. September 18, 2017
Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results September 18, 2017 Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationIntroduction to Antimicrobial Therapy
Introduction to Antimicrobial Therapy Christine Kubin, Pharm.D., BCPS Clinical Pharmacist, Infectious Diseases Case #2 68 y.o. female with HTN, anxiety with chest pain symptoms 7/27/05: Cath - 3 vessel
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of Change in the approach to the administration of empiric antimicrobial therapy Increased
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationProceedings of the 13th International Congress of the World Equine Veterinary Association WEVA
www.ivis.org Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA October 3-5, 2013 Budapest, Hungary Reprinted in IVIS with the Permission of the WEVA Organizers
More information